<p>Voya Investment Management LLC 在最近向证券交易委员会的披露中表示，其在 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）的持股在第三季度减少了 17.7%。该基金在季度内出售了 80,326 股后，持有该公司 373,494 股股票。截至其最近的 SEC 备案，Voya Investment Management LLC 持有的 Cencora 股票约占 0.19%，价值 116,728,000 美元。</p>
<ul>
<li>在下跌市场中 S&amp;P 500 的前三大赢家</li>
</ul>
<p>其他机构投资者最近也增加或减少了对该公司的持股。Contravisory Investment Management Inc. 在第三季度将其在 Cencora 的持股增加了 1.6%。Contravisory Investment Management Inc. 目前持有 5,469 股该公司股票，价值 1,709,000 美元，在此期间又购买了 87 股。Wedmont Private Capital 在第三季度将其在 Cencora 的持股增加了 11.4%。Wedmont Private Capital 目前持有 2,830 股该公司股票，价值 874,000 美元，在此期间又购买了 289 股。捷克国家银行在第三季度将其在 Cencora 的持股增加了 16.8%。捷克国家银行目前持有 49,240 股该公司股票，价值 15,389,000 美元，在上个季度又购买了 7,075 股。Assenagon Asset Management S.A. 在第三季度将其在 Cencora 的持股增加了 915.3%。Assenagon Asset Management S.A. 目前持有 353,021 股该公司股票，价值 110,330,000 美元，在此期间又购买了 318,250 股。最后，Carolina Wealth Advisors LLC 在第三季度将其在 Cencora 的持股增加了 27.9%。Carolina Wealth Advisors LLC 目前持有 6,624 股该公司股票，价值 2,070,000 美元，在上个季度又购买了 1,444 股。目前，97.52% 的股票由机构投资者和对冲基金持有。</p>
<h2>华尔街分析师观点</h2>
<p>COR 已成为多份研究报告的主题。TD Cowen 在 11 月 10 日的报告中将 Cencora 的目标价从 350.00 美元上调至 400.00 美元，并给予该股票 &#34;买入&#34; 评级。巴克莱在 12 月 8 日的研究报告中对 Cencora 的股票进行了覆盖，设定了 &#34;增持&#34; 评级和 400.00 美元的目标价。罗伯特·W·贝尔德在周二的研究报告中为 Cencora 的股票设定了 392.00 美元的目标价。华尔街 Zen 在 11 月 28 日的研究报告中将 Cencora 的股票评级从 &#34;买入&#34; 下调至 &#34;持有&#34;。最后，瑞穗在 11 月 6 日的研究报告中将 Cencora 的目标价从 340.00 美元上调至 380.00 美元，并给予该股票 &#34;跑赢大盘&#34; 评级。一位分析师给予该股票 &#34;强烈买入&#34; 评级，八位分析师给予 &#34;买入&#34; 评级，四位分析师给予 &#34;持有&#34; 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;适度买入&#34;，平均目标价为 373.25 美元。</p>
<ul>
<li>Walgreens 股票反弹：WBA 可能成为强劲买入的四个理由</li>
</ul>
<p><strong>查看我们关于 Cencora 的最新研究报告</strong></p>
<h2>Cencora 股票表现</h2>
<p>Cencora 股票在周五开盘价为 341.07 美元。该公司的债务与股本比率为 4.32，流动比率为 0.90，速动比率为 0.55。该公司的 50 日移动平均价格为 346.49 美元，200 日移动平均价格为 313.01 美元。该公司的市值为 661.6 亿美元，市盈率为 42.90，市盈率增长比率为 1.62，贝塔值为 0.63。Cencora, Inc. 的 12 个月低点为 223.92 美元，12 个月高点为 377.54 美元。</p>
<ul>
<li>Teva Pharma 是参与仿制药重新崛起的方式</li>
</ul>
<p>Cencora（纽约证券交易所代码：COR - 获取免费报告）最近在 11 月 5 日宣布了其财报。该公司报告季度每股收益为 3.84 美元，超出市场共识预期的 3.79 美元，超出 0.05 美元。Cencora 的股本回报率为 227.15%，净利润率为 0.48%。该公司在本季度的收入为 837.3 亿美元，而市场共识预期为 833.6 亿美元。去年同期，该公司每股收益为 3.34 美元。该公司的收入同比增长了 5.9%。Cencora 已设定其 2026 财年的指导目标为每股收益 17.450-17.75 美元。研究分析师平均预测 Cencora, Inc. 本财年的每股收益为 15.37 美元。</p>
<h2>Cencora 增加股息</h2>
<p>该公司最近还披露了季度股息，已于 12 月 1 日支付。11 月 14 日的股东获得了每股 0.60 美元的股息。除息日期为 11 月 14 日。这代表着每年 2.40 美元的股息和 0.7% 的收益率。这比 Cencora 之前的季度股息 0.55 美元有所增加。Cencora 的股息支付比率（DPR）目前为 30.19%。</p>
<h2>内部活动</h2>
<p>在其他新闻中，首席执行官 Robert P. Mauch 于 10 月 20 日星期一出售了 5,097 股该股票。该股票以平均价格 326.80 美元出售，总交易额为 1,665,699.60 美元。交易完成后，首席执行官直接持有该公司 37,940 股，价值约 12,398,792 美元。这代表着其持股减少了 11.84%。该交易已在 SEC 的备案中披露，可以通过此链接访问。目前，10.80% 的股票由内部人士持有。</p>
<h2>关于 Cencora</h2>
<p>（免费报告）</p>
<p>Cencora（纽约证券交易所代码：COR）是一家全球医疗服务和药品分销公司，提供跨药品供应链的端到端解决方案。该公司的核心业务包括批发药品分销、专科药品分销和专科药房的运营，辅以物流、冷链管理和其他旨在支持复杂和温度敏感疗法的履行服务。</p>
<p>除了实体分销，Cencora 还为制药制造商和医疗服务提供者提供一系列商业和以患者为中心的服务。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Cencora</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>MarketBeat 周回顾 – 12/15 - 12/19</li>
<li>为什么除息日对投资者来说重要？</li>
<li>耐克在收益上超出预期，但在中国面临挑战并遭遇关税</li>
</ul>
<p><strong>想看看其他对 COR 感兴趣的对冲基金持有哪些股票？</strong> 访问 HoldingsChannel.com，获取 Cencora, Inc.（NYSE:COR - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 Cencora 1000 美元吗？</h2>
<p>在考虑 Cencora 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cencora 并不在名单上。</p>
<p>虽然 Cencora 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>Voya Investment Management LLC 在第三季度减少了对 Cencora, Inc. 的持股比例，降幅为 17.7%，目前持有 373,494 股，市值为 1.1673 亿美元。其他机构投资者也调整了他们的持仓。分析师对 Cencora 的评级褒贬不一，普遍共识为 “适度买入”，平均目标价为 373.25 美元。Cencora 报告了强劲的盈利和收入增长，并增加了股息。该股票的市值为 661.6 亿美元，市盈率为 42.90</p>

<p>Voya Investment Management LLC decreased its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 17.7% during the 3rd quarter, according to its most recent disclosure with the Securities &amp; Exchange Commission. The fund owned 373,494 shares of the company's stock after selling 80,326 shares during the quarter. Voya Investment Management LLC owned about 0.19% of Cencora worth $116,728,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Voya Investment Management LLC 在最近向证券交易委员会的披露中表示，其在 Cencora, Inc.（纽约证券交易所代码：COR - 免费报告）的持股在第三季度减少了 17.7%。该基金在季度内出售了 80,326 股后，持有该公司 373,494 股股票。截至其最近的 SEC 备案，Voya Investment Management LLC 持有的 Cencora 股票约占 0.19%，价值 116,728,000 美元。</p>
</div><ul>
<li>Top 3 S&amp;P 500 Winners in a Losing Market</li>
</ul>
<div class="lb-trans"><ul>
<li>在下跌市场中 S&amp;P 500 的前三大赢家</li>
</ul>
</div><p>Other institutional investors have also recently added to or reduced their stakes in the company. Contravisory Investment Management Inc. grew its holdings in Cencora by 1.6% in the third quarter. Contravisory Investment Management Inc. now owns 5,469 shares of the company's stock valued at $1,709,000 after purchasing an additional 87 shares during the period. Wedmont Private Capital grew its stake in shares of Cencora by 11.4% during the 3rd quarter. Wedmont Private Capital now owns 2,830 shares of the company's stock valued at $874,000 after buying an additional 289 shares during the period. Czech National Bank increased its holdings in shares of Cencora by 16.8% during the 3rd quarter. Czech National Bank now owns 49,240 shares of the company's stock worth $15,389,000 after buying an additional 7,075 shares during the last quarter. Assenagon Asset Management S.A. raised its position in shares of Cencora by 915.3% in the 3rd quarter. Assenagon Asset Management S.A. now owns 353,021 shares of the company's stock worth $110,330,000 after buying an additional 318,250 shares during the period. Finally, Carolina Wealth Advisors LLC boosted its holdings in Cencora by 27.9% in the third quarter. Carolina Wealth Advisors LLC now owns 6,624 shares of the company's stock valued at $2,070,000 after acquiring an additional 1,444 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>其他机构投资者最近也增加或减少了对该公司的持股。Contravisory Investment Management Inc. 在第三季度将其在 Cencora 的持股增加了 1.6%。Contravisory Investment Management Inc. 目前持有 5,469 股该公司股票，价值 1,709,000 美元，在此期间又购买了 87 股。Wedmont Private Capital 在第三季度将其在 Cencora 的持股增加了 11.4%。Wedmont Private Capital 目前持有 2,830 股该公司股票，价值 874,000 美元，在此期间又购买了 289 股。捷克国家银行在第三季度将其在 Cencora 的持股增加了 16.8%。捷克国家银行目前持有 49,240 股该公司股票，价值 15,389,000 美元，在上个季度又购买了 7,075 股。Assenagon Asset Management S.A. 在第三季度将其在 Cencora 的持股增加了 915.3%。Assenagon Asset Management S.A. 目前持有 353,021 股该公司股票，价值 110,330,000 美元，在此期间又购买了 318,250 股。最后，Carolina Wealth Advisors LLC 在第三季度将其在 Cencora 的持股增加了 27.9%。Carolina Wealth Advisors LLC 目前持有 6,624 股该公司股票，价值 2,070,000 美元，在上个季度又购买了 1,444 股。目前，97.52% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>COR has been the topic of a number of research reports. TD Cowen raised their price objective on Cencora from $350.00 to $400.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, November 10th. Barclays initiated coverage on shares of Cencora in a research report on Monday, December 8th. They set an &#34;overweight&#34; rating and a $400.00 target price for the company. Robert W. Baird set a $392.00 price objective on shares of Cencora in a research report on Tuesday. Wall Street Zen downgraded shares of Cencora from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, November 28th. Finally, Mizuho upped their price target on shares of Cencora from $340.00 to $380.00 and gave the stock an &#34;outperform&#34; rating in a research report on Thursday, November 6th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the company's stock. According to MarketBeat.com, the company has an average rating of &#34;Moderate Buy&#34; and an average target price of $373.25.</p>
<div class="lb-trans"><p>COR 已成为多份研究报告的主题。TD Cowen 在 11 月 10 日的报告中将 Cencora 的目标价从 350.00 美元上调至 400.00 美元，并给予该股票 &#34;买入&#34; 评级。巴克莱在 12 月 8 日的研究报告中对 Cencora 的股票进行了覆盖，设定了 &#34;增持&#34; 评级和 400.00 美元的目标价。罗伯特·W·贝尔德在周二的研究报告中为 Cencora 的股票设定了 392.00 美元的目标价。华尔街 Zen 在 11 月 28 日的研究报告中将 Cencora 的股票评级从 &#34;买入&#34; 下调至 &#34;持有&#34;。最后，瑞穗在 11 月 6 日的研究报告中将 Cencora 的目标价从 340.00 美元上调至 380.00 美元，并给予该股票 &#34;跑赢大盘&#34; 评级。一位分析师给予该股票 &#34;强烈买入&#34; 评级，八位分析师给予 &#34;买入&#34; 评级，四位分析师给予 &#34;持有&#34; 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 &#34;适度买入&#34;，平均目标价为 373.25 美元。</p>
</div><ul>
<li>Walgreens Stock Rally: 4 Reasons WBA Could Be a Strong Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>Walgreens 股票反弹：WBA 可能成为强劲买入的四个理由</li>
</ul>
</div><p><strong>View Our Latest Research Report on Cencora</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Cencora 的最新研究报告</strong></p>
</div><h2>Cencora Stock Performance</h2>
<div class="lb-trans"><h2>Cencora 股票表现</h2>
</div><p>Cencora stock opened at $341.07 on Friday. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The firm's fifty day moving average price is $346.49 and its 200 day moving average price is $313.01. The company has a market capitalization of $66.16 billion, a price-to-earnings ratio of 42.90, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63. Cencora, Inc. has a 12-month low of $223.92 and a 12-month high of $377.54.</p>
<div class="lb-trans"><p>Cencora 股票在周五开盘价为 341.07 美元。该公司的债务与股本比率为 4.32，流动比率为 0.90，速动比率为 0.55。该公司的 50 日移动平均价格为 346.49 美元，200 日移动平均价格为 313.01 美元。该公司的市值为 661.6 亿美元，市盈率为 42.90，市盈率增长比率为 1.62，贝塔值为 0.63。Cencora, Inc. 的 12 个月低点为 223.92 美元，12 个月高点为 377.54 美元。</p>
</div><ul>
<li>Teva Pharma is the way to play the re-rise of generic drugs</li>
</ul>
<div class="lb-trans"><ul>
<li>Teva Pharma 是参与仿制药重新崛起的方式</li>
</ul>
</div><p>Cencora (NYSE:COR - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. During the same period last year, the firm earned $3.34 earnings per share. The company's revenue was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, research analysts forecast that Cencora, Inc. will post 15.37 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Cencora（纽约证券交易所代码：COR - 获取免费报告）最近在 11 月 5 日宣布了其财报。该公司报告季度每股收益为 3.84 美元，超出市场共识预期的 3.79 美元，超出 0.05 美元。Cencora 的股本回报率为 227.15%，净利润率为 0.48%。该公司在本季度的收入为 837.3 亿美元，而市场共识预期为 833.6 亿美元。去年同期，该公司每股收益为 3.34 美元。该公司的收入同比增长了 5.9%。Cencora 已设定其 2026 财年的指导目标为每股收益 17.450-17.75 美元。研究分析师平均预测 Cencora, Inc. 本财年的每股收益为 15.37 美元。</p>
</div><h2>Cencora Increases Dividend</h2>
<div class="lb-trans"><h2>Cencora 增加股息</h2>
</div><p>The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a dividend of $0.60 per share. The ex-dividend date was Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. This is a boost from Cencora's previous quarterly dividend of $0.55. Cencora's dividend payout ratio (DPR) is presently 30.19%.</p>
<div class="lb-trans"><p>该公司最近还披露了季度股息，已于 12 月 1 日支付。11 月 14 日的股东获得了每股 0.60 美元的股息。除息日期为 11 月 14 日。这代表着每年 2.40 美元的股息和 0.7% 的收益率。这比 Cencora 之前的季度股息 0.55 美元有所增加。Cencora 的股息支付比率（DPR）目前为 30.19%。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In other news, CEO Robert P. Mauch sold 5,097 shares of the stock in a transaction that occurred on Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. This represents a 11.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 10.80% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Robert P. Mauch 于 10 月 20 日星期一出售了 5,097 股该股票。该股票以平均价格 326.80 美元出售，总交易额为 1,665,699.60 美元。交易完成后，首席执行官直接持有该公司 37,940 股，价值约 12,398,792 美元。这代表着其持股减少了 11.84%。该交易已在 SEC 的备案中披露，可以通过此链接访问。目前，10.80% 的股票由内部人士持有。</p>
</div><h2>About Cencora</h2>
<div class="lb-trans"><h2>关于 Cencora</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Cencora NYSE: COR is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company's core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.</p>
<div class="lb-trans"><p>Cencora（纽约证券交易所代码：COR）是一家全球医疗服务和药品分销公司，提供跨药品供应链的端到端解决方案。该公司的核心业务包括批发药品分销、专科药品分销和专科药房的运营，辅以物流、冷链管理和其他旨在支持复杂和温度敏感疗法的履行服务。</p>
</div><p>Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.</p>
<div class="lb-trans"><p>除了实体分销，Cencora 还为制药制造商和医疗服务提供者提供一系列商业和以患者为中心的服务。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Cencora</li>
<li>Should You Add These Warren Buffett Stocks to Your Portfolio?</li>
<li>This ETF Caught a Major Tailwind After the Fed’s Rate Cut</li>
<li>What is MarketRank™? How to Use it</li>
<li>MarketBeat Week in Review – 12/15 - 12/19</li>
<li>Why is the Ex-Dividend Date Significant to Investors?</li>
<li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Cencora</li>
<li>你应该将这些沃伦·巴菲特的股票加入你的投资组合吗？</li>
<li>这只 ETF 在美联储降息后获得了重大助力</li>
<li>什么是 MarketRank™？如何使用它</li>
<li>MarketBeat 周回顾 – 12/15 - 12/19</li>
<li>为什么除息日对投资者来说重要？</li>
<li>耐克在收益上超出预期，但在中国面临挑战并遭遇关税</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding COR?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:COR - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他对 COR 感兴趣的对冲基金持有哪些股票？</strong> 访问 HoldingsChannel.com，获取 Cencora, Inc.（NYSE:COR - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUNPUg" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=COR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Cencora Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 Cencora 1000 美元吗？</h2>
</div><p>Before you consider Cencora, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Cencora 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cencora wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Cencora 并不在名单上。</p>
</div><p>While Cencora currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Cencora 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Voya Investment Management LLC 减少了其在 Cencora, Inc. $COR 的持仓